期刊文献+

光敏功能化载药系统CPTPP-FA-LCOS的制备及性能 被引量:1

Preparation and Properties of Drug Delivery System CPTPP-FA-LCOS with Photosensitive Function
原文传递
导出
摘要 通过酰化反应将叶酸(FA)、两亲性亚油酰化壳寡糖(LCOS)连接到羧基取代的四苯基卟啉(TPP)化合物5-(4-羧基苯基)-10,15,20-三苯基卟啉(CPTPP)结构上,得到了潜在光敏功能化载药系统CPTPP-FA-LCOS。利用FTIR、UV-Vis、TEM、FL对CPTPP-FA-LCOS的结构进行了表征,并运用表面张力法测定了其临界胶束质量浓度(CMC)。结果表明:CPTPP-FA-LCOS的CMC=2.5×10^(-3)g/L,其可形成稳定的球形纳米胶束,粒径在70~120 nm。四唑盐(MTT)比色法的初步实验结果表明:在光照条件下,0.4 g/L的CPTPP-FA-LCOS即可使He La细胞存活率降至50%以下,表明CPTPP-FA-LCOS具有明显的光毒性。 A photosensitive drug delivery system CFFPP-FA-LCOS was obtained by acylation reaction of folic acid (FA), amphiphilic N-linoleyl chitosan oligosaccharide (LCOS) with carboxyl substituted meso-tetraphenylporphyrin (TPP) of 5- (4-carboxyl) phenyl-10,15,20-triphenyl porphyrin ( CPTPP ). The chemical structure of CPTPP-FA-LCOS was characterized by FTIR, UV-Vis,TEM, and fluorescence spectrum. The critical micefle concentration (CMC) of CFI'PP-FA-LCOS was also determined using surface tension method. The results showed that CMC value of CPTPP-FA-LCOS was 2.5× 10-3 g/L. CPTPP-FA-LCOS could form stable spherical nano-micelles with a particle size between 70 and 120 nm. The results of preliminary MTI" (methyl thiazolyl tetrazolim ) suggested that 0. 4 g/L CPTPP-FA-LCOS could make the HeLa cell viability reduce to less than 50% under the light condition, indicating that CPTPP-FA-LCOS had obvious phototoxicity.
出处 《精细化工》 EI CAS CSCD 北大核心 2017年第5期494-498,共5页 Fine Chemicals
基金 国家自然科学基金(21601068/21471069/21302071) 江苏省高等自然科学研究面上项目(14KJB150006) 江苏省博士后科研资助计划项目(1401050C) 江苏大学高级人才科研启动基金(14JDG054)~~
关键词 光动力疗法 光敏剂 亚油酰化壳寡糖 叶酸 功能材料 photodynamic therapy photosensitizer N-linoleyl chitosan oligosaccharide folic acid functional materials
  • 相关文献

参考文献2

二级参考文献38

  • 1李步洪,谢树森.功能型光敏剂的研究进展[J].中国激光医学杂志,2007,16(3):179-185. 被引量:13
  • 2Mitton D, Ackroyd R. A brief overview of photodynamic therapy in Europe[J]. Photodiagnosis Photodyn Ther, 2008,5(2):103.
  • 3Roelandts R.The history of phototherapy: Something new under the sun? [J]. J Am Acad Dermatol, 2002, 46 (6) : 926.
  • 4Wainwright M.Photodynamic therapy: the development of new photosensitisers[J]. Anticancer Agents Med Chem, 2008, 8(3): 280.
  • 5Dougherty T J, Gomer C J, Henderson BW, et al. Photodynamic therapy[J]. J Natl Cancer Inst, 1998,90 ( 12 ) : 889.
  • 6Shuler MF, Borrillo JL, Ho AC. Photodynamic therapy update[J]. Curt Opin Ophthalmol, 2001,12 (3) : 202.
  • 7Schein OD, Bressler NM, Price E Photodynamic therapy with verteporfin: observations on the introduction of a new treatment into clinical practice[J]. Arch Ophthalmol, 2005,123(1): 58.
  • 8Kennedy JC, Marcus SL, Pottier RH. Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA) : mechanisms and clinical results[J]. J Clin Laser MedSurg, 1996,14(5) : 289.
  • 9Molinari A, Bombelli C, Mannino S, et al. m-THPC- mediated photodynamic therapy of malignant gliomas: as- sessment of a new transfection strategy[J]. Int J Cancer, 2007,121(5) : 1 149.
  • 10Ackroyd R, Brown N J, Davis MF, et al. Photodynamic therapy for dysplastic Barrett' s oesophagus: a prospective, double blind, randomised, placebo controlled trial [J]. Gut,2000,47(5) :612.

共引文献3

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部